MedWatch

Zealand CEO: cancelled agreement is positive news

Swiss drug group Helsinn has returned the rights to a Zealand-developed drug to the Danish company and thus, cancelled an almost nine year old license agreement. However, Zealand’s CEO Britt Meelby Jensen is far from pessimistic.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Reuters: Kinesere vil købe J&J's diabetesforretning

Amerikanske Johnson & Johnson kan være på vej til at sælge sin forretning for diabetesudstyr for godt 24 mia. kr., efter flere kinesiske aktører ifølge Reuters har vist interesse i at overtage forretningsdelen.

Related articles